By Heather Landi
Digital health company Ro has raised half a billion dollars to scale up its platform that includes online pharmacy services, telehealth and in-home care. The round values New York City-based Ro at $5 billion, according to media reports.
read more
By Fraiser Kansteiner
The FDA blessed Catalent's Bloomginton, Indiana, facility with an emergency nod to produce the active ingredient for Johnson & Johnson's COVID-19 vaccine and ship out finished doses, Bloomberg first reported Tuesday. The CDMO could subsequently release millions of vials that have already been packaged and inspected.
read more
By Beth Snyder Bulik
AstraZeneca is staring down another public relations ordeal as U.S. regulators push back on the COVID-19 vaccine data it released Monday to much fanfare. At issue? The wording of a press release, which so troubled a key trial monitoring committee that U.S. officials sent out their own skeptical statement in the middle of the night.
read more
By Arlene Weintraub
A combination of two antibodies, casirivimab and imdevimab, lowered the risk of hospitalization or death by 70% in a phase 3 trial in high-risk patients with COVID-19, Regeneron and its partner Roche said. The drug combo also retained its potency against five major variants of concern.
read more
By Conor Hale
The people who bring you lunch can now also deliver a COVID-19 diagnostic test, as screening for the pandemic disease continues to become a more ubiquitous part of everyday life.
read more
By Robert King
The Senate is likely to consider this week legislation to extend a moratorium on a 2% cut to Medicare payments, top American Hospital Association officials told reporters.
read more
By Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale
Texas will become the fourth state to open vaccinations to all adults, well ahead of President Biden's May 1 target for all states. With Europe facing a third COVID wave, Germany has tightened restrictions. Regeneron and Roche revealed strong data for their COVID-19 antibody cocktail. AstraZeneca's latest vaccine misstep piles onto the company's public relations problems.
read more
By Conor Hale
The two largest dialysis providers in the U.S. are teaming up to pursue a business proposition that might seem antithetical in nearly any other field or at any other time outside of a worldwide pandemic. They aim to help get patients out of their respective clinics and have them access treatment from inside their own homes.
read more
By Kevin Dunleavy
After developing a coronavirus vaccine with partner BioNTech in record time, Pfizer will attempt to apply mRNA technology to the development of other vaccines on its own, CEO Albert Bourla said in an interview with The Wall Street Journal.
read more
By Fraiser Kansteiner
Europe could soon approve the Dutch plant ensnared in the AstraZeneca vaccine spat between the EU and the U.K., Rudd Dobber, president of the company's BioPharmaceuticals business, said. The facility, run by AZ's manufacturing partner Halix, would supply vaccines to both Britain and the EU.
read more
By Nick Paul Taylor
Premas Biotech and Oramed have joined forces to start an oral COVID-19 vaccine startup, Oravax Medical. The biotech starts life with exclusive licenses from both companies and plans to get into the clinic in the second quarter.
read more
